BIOTRON LIMITED — Capital/Financing Update 2025

Dec 1, 2025

==> picture [230 x 35] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: mmora@biotron.com.au Website: www.biotron.com.au

2 December 2025

The Manager Companies ASX Limited 20 Bridge Street SYDNEY NSW 2000

(1 page by email)

Dear Madam,

COMPLETION OF TRANCHE 2 OF PLACEMENT

The Directors of Biotron Limited (‘Biotron’ or ‘the Company’) (ASX: BIT) are pleased to advise that Tranche 2 of a Placement has been successfully completed, raising $402,740 (before costs).

Tranche 1, completed on 22 October 2025, raised $597,260 (before costs). In total, the Placement raised $1 million (before costs), at an issue price of $0.003 per share, with 1 attaching option ($0.02 expiring 24 November 2027) for every 2 shares issued.

Monies raised under the Placement will be used to fund the development of the products associated with the recent acquisition by Biotron of Sedarex Limited.

The second tranche of the Placement and the acquisition of Sedarex Limited were approved by Biotron shareholders at the Company’s recent AGM. The acquisition marks a pivotal moment for Biotron, expanding its pipeline with a late-stage clinical asset while continuing its antiviral mission.

The Placement was lead managed by Peak Asset Management.

This announcement has been approved by the Company’s Managing Director.

Yours sincerely

==> picture [97 x 55] intentionally omitted <==

Marcelo Mora Company Secretary

pjn12807